Effects of Metformin combined with Ethinylestradiol-cyproterone acetate in treatment of adolescent obese patients with polycystic ovary syndrome
Objective:To observe effects of Metformin combined with Ethinylestradiol-cyproterone acetate in treatment of adolescent obese patients with polycystic ovary syndrome(PCOS).Methods:The clinical data of 70 adolescent obese patients with PCOS who were treated in this hospital from March 2022 to January 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group(36 cases)and observation group(34 cases).The control group was treated with Ethinylestradiol-cyproterone acetate,while the observation group was treated with Metformin on the basis of that of the control group.The sign indexes[body mass index(BMI),waist-hip ratio(WHR),hirsutism and acne score]levels,the sex hormone[sex hormone binding globulin(SHBG),follicle stimulating hormone(FSH),estradiol(E2),luteinizing hormone(LH),testosterone(T)]levels,the glucose and lipid metabolism indexes[fasting blood glucose(FPG),fasting insulin(FINS),total cholesterol(TC)]levels,the levels of serum anti-mullerian hormone(AMH)and microfibril-associated protein 5(MFAP5),and the incidence of adverse reactions during treatment were compared between the two groups before and after the treatment.Results:After the treatment,the WHR,BMI,acne and hirsutism scores of the observation group were lower than those of the control group,and the differences were statistically significant(P<0.05).After the treatment,the level of SHBG in the observation group was higher than that in the control group,the levels of FSH,E2,LH and T were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of TC,FPG,FINS,AMH and MFAP5 in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Metformin combined with Ethinylestradiol-cyproterone acetate in the treatment of the adolescent obese patients with PCOS can reduce the levels of physical signs as well as glucose and lipid metabolism indexes,the levels of AMH and MFAP5,and improve the levels of sex hormone.Moreover,it is superior to single Ethinylestradiol-cyproterone acetate treatment.
AdolescenceObesityPolycystic ovary syndromeMetforminEthinylestradiol-cyproterone acetateGlucose and lipid metabolismSex hormone
万方数据
维普
